Pharmaceutical News and Articles

A-Fib Risk Drops Soon After Quitting Smoking

Smokers who make the decision to quit will see almost immediate health benefits, including a quick drop in their risk for atrial fibrillation, new research show

Source of Missouri Bird Flu Case Still Unknown, Could Be a 'One-Off': CDC

In a case that continues to confound scientists, U.S. health officials said Thursday that they still don t know how a Missouri patient caught the bird flu and t

Over 5 Million Americans Could Benefit If Psilocybin Approved for Depression: Study

it might help ease tough-to-treat depression.The drug is now under consideration by the FDA as a possible new treatment for depression.Just how many Americans m

1 in 3 Store-Bought Cinnamon Samples Tested Have Elevated Lead Levels

One third of cinnamon products tested by Consumer Reports contained elevated levels of lead, the watchdog agency warned Thursday.The finding follows concerns ab

Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

SAN DIEGO, Sept. 12, 2024. Neurocrine Biosciences, Inc. today announced that its ERUDITE Phase 2 clinical study of investigational compound luvadaxistat (NBI-10

FDA Approves Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

At Least One in Five People Has Obesity in Each U.S. State

Statistics from 2023 on U.S. obesity rates reveal that in every U.S. state, one in every five people now has obesity, according to data released Thursday by the

Risk for Venous Thromboembolism Up for Those With Sickle Cell Trait

Individuals with sickle cell trait (SCT) have an increased risk for venous thromboembolism (VTE), according to a study published online Sept. 12 in Blood Advanc

Long-Course Chemoradiotherapy Preferred TNT Regimen for Rectal Cancer

For patients with locally advanced rectal cancer pursuing organ preservation, long-course chemoradiotherapy (LCCRT) is the preferred total neoadjuvant therapy (